We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+32.82%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.14B
AUM Growth
+$551M
Cap. Flow
+$421M
Cap. Flow %
37.05%
Top 10 Hldgs %
39.86%
Holding
141
New
51
Increased
36
Reduced
11
Closed
41

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$18.2M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$10.6M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$10.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.48M
5
SRACU
Stable Road Acquisition Corp. Unit
SRACU
+$4.41M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$9.51M
3
SNN icon
Smith & Nephew
SNN
+$8.66M
4
BAX icon
Baxter International
BAX
+$4.96M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 26.48%
2 Industrials 0.92%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
101
DELISTED
Adverum Biotechnologies
ADVM
– –
-10,000
Closed -$545K
AMGN icon
102
CALL
Amgen
AMGN
$224B
– –
-100,000
Closed -$19.4M
ARVN icon
103
Arvinas
ARVN
$588M
– –
-64,209
Closed -$1.38M
AXSM icon
104
Axsome Therapeutics
AXSM
$11.1B
– –
-58,519
Closed -$1.18M
BAX icon
105
Baxter International
BAX
$14.3B
– –
-60,000
Closed -$4.96M
CHRS icon
106
CALL
Coherus Oncology
CHRS
$187M
– –
-400,000
Closed -$8.1M
CHRS icon
107
Coherus Oncology
CHRS
$187M
– –
-50,000
Closed -$1.01M
CSTL icon
108
Castle Biosciences
CSTL
$985M
– –
-131,718
Closed -$2.38M
CYTK icon
109
Cytokinetics
CYTK
$10.6B
– –
-188,096
Closed -$2.14M
GILD icon
110
Gilead Sciences
GILD
$168B
– –
-150,000
Closed -$9.51M
IBB icon
111
CALL
iShares Biotechnology ETF
IBB
$9.81B
– –
-109,200
Closed -$10.9M
LAB icon
112
CALL
Standard BioTools
LAB
$309M
– –
-300,000
Closed -$1.39M
MJ icon
113
PUT
Amplify Alternative Harvest ETF
MJ
$109M
– –
-58,333
Closed -$14.5M
REGN icon
114
CALL
Regeneron Pharmaceuticals
REGN
$82.1B
– –
-50,000
Closed -$13.9M
REGN icon
115
Regeneron Pharmaceuticals
REGN
$82.1B
– –
-40,000
Closed -$11.1M
SAGE
116
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-10,000
Closed -$1.4M
SNN icon
117
CALL
Smith & Nephew
SNN
$12.6B
– –
-265,000
Closed -$12.8M
SNN icon
118
Smith & Nephew
SNN
$12.6B
– –
-180,000
Closed -$8.66M
STAA icon
119
CALL
STAAR Surgical
STAA
$1.24B
– –
-231,200
Closed -$5.96M
SUPN icon
120
PUT
Supernus Pharmaceuticals
SUPN
$2.73B
– –
-100,000
Closed -$2.75M
TNDM icon
121
Tandem Diabetes Care
TNDM
$1.63B
– –
-40,000
Closed -$2.36M
UTHR icon
122
United Therapeutics
UTHR
$22.1B
– –
-39,000
Closed -$3.11M
WAT icon
123
CALL
Waters Corp
WAT
$40.7B
– –
-50,000
Closed -$11.2M
ZYME icon
124
Zymeworks
ZYME
$1.73B
– –
-50,000
Closed -$1.24M
RNTX
125
Rein Therapeutics
RNTX
$69.9M
– –
-6,777
Closed -$91K
2 3 4
5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Pura Vida Investments held 141 positions worth $1.14B, up 94% from $585M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Pura Vida Investments deployed $421M of net new capital in Q4 2019, opening 51 new positions and adding to 36 existing holdings. Its largest new stake was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 40% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Establishment Labs, an estimated $1.39M trimmed.

  • Pura Vida Investments's largest Q4 2019 buy was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2019, an estimated $18.2M increase.
  • Pura Vida Investments's biggest Q4 2019 reduction was Establishment Labs, cutting an estimated $1.39M.
  • Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q4 2019, selling an estimated $11.1M.
  • Pura Vida Investments's ten largest holdings make up 40% of its $1.14B portfolio in Q4 2019.
  • Pura Vida Investments opened 51 new positions and closed 41 in Q4 2019.
  • Pura Vida Investments's portfolio value rose 94% quarter-over-quarter to $1.14B.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.